Intravitreal Chemotherapy (IViC)
Treatment for Retinoblastoma
Typical Dosage: e.g., Melphalan 20-40 "g, Topotecan 10-30 "g
Effectiveness
90%
Safety Score
50%
Clinical Trials
40
Participants
2.5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
50
DangerousModerateSafe
Treatment Details
Dosage Range
e.g., Melphalan 20-40 "g, Topotecan 10-30 "g
Time to Effect
2-4 weeks
Treatment Duration
1-3 months
Evidence Quality
MODERATEConfidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$2,000
Monitoring:$30,000
Side Effect Mgmt:$1,000
Total Annual:$33,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
19
Outcome-Based Costs
Cost per Responder
$37,714
Cost per Remission
$37,714
Comparison vs Enucleation (salvage for vitreous seeds)
Cost Difference
+$15,500/year
More expensive
QALY Difference
+0.75 QALYs
Better outcomes
Dominance
No dominance
Intravitreal Chemotherapy (IViC) Outcomes
for Retinoblastoma
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+88%
Remission Rate
+88%
Common Side Effects
Vitreous hemorrhage
+10%
Retinal toxicity
+10%
Hyphema
+10%
Retinal detachment
+5%
Endophthalmitis
+1%
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov